Skip to main content

Table 3 Calculated rates of change per month across all assessed parameters while on dupilumab according to the linear models

From: The “real life” efficacy of dupilumab is independent of initial polyp size and concomitant steroids in CRSwNP

 

Initial TPS ≤ 4

Initial TPS ≥ 5

P value of difference

TPS [RCpM]

0.78

0.76

0.57

SNOT-22 [RCpM]

0.88

0.83

0.07

Sniffin´ sticks [LCpM]

0.54

0.75

0.08

EQ-5D-3L [RCpM]

0.99

0.99

0.67

PHQ-2 [RCpM]

0.83

0.85

0.29

ACT [LCpM]

0.21

0.19

0.8

Mini AQLQ [LCpM]

1.59

2.26

0.13

  1. RCpM relative change per month, LCpM linear change per month, TPS total polyp score, SNOT-22 Sino Nasal Outcome Test 22, EQ5D-3L European Quality of Life Five Dimension 3 Level, PHQ-2 Patient Health Questionnaire 2, ACT Asthma Control Test, Mini AQLQ Mini Asthma Quality of Life Questionnaire
Back to article page

Journal of Otolaryngology - Head & Neck Surgery

ISSN: 1916-0216

Contact us